Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3 and 2 bp insertion in exon3.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-SHFL, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
C19orf66 also known as Shiftless or C6orf166 is a protein with a molecular mass of approximately 27 kDa. It functions as an inhibitor of viral RNA replication. Research shows that C19orf66 disrupts viral protein synthesis by interacting with viral factors and initiating their degradation making it important for antiviral defense. This protein is expressed in various tissues with high levels detected in immune-related cells suggesting its role in innate immune response.
Biological function summary
C19orf66 plays an essential role in modulating immune response against viral pathogens. Its action involves the inhibition of viral replication which helps in controlling the spread of the infection within the host. C19orf66 does not typically form part of large protein complexes but it exerts its effect through direct interaction with viral components preventing their proper assembly and function.
Pathways
C19orf66 is involved in important antiviral defense mechanisms including those that overlap with the interferon signaling pathway. This protein interacts with interferon-stimulated genes enhancing the host's capability to limit viral infections. Although not directly part of an extensive pathway like NF-kB or MAPK C19orf66 contributes to antiviral defense through its relationship with proteins that are engaged by these pathways during immune responses.
C19orf66 shows implications in viral infections and may play a role in diseases where the immune response is compromised such as chronic viral infections. It has a functional connection with viral proteins which aids in limiting the replication and persistence of viruses. Studies explore its potential usefulness as a therapeutic target especially considering its ability to inhibit the replication of various viruses without directly impacting host cellular machinery.
